newsfilter
← Latest News
Business Wire·

AIM ImmunoTech Board Files Definitive Proxy Statement and Sends Letter to Shareholders

Highlights Significant Progress Made in Recent Years – and Especially Over Past 18 Months – in Repurposing Lead Drug Ampligen in Oncology to Benefit Patients and All Shareholders Calls on Shareholders to Support Continued Positive Momentum by Re-